Thresholds for adjunctive medication usage and probability of initiating injectable naltrexone

Area of Science:

• Addiction Medicine
• Pharmacology
• Clinical Trials

Background:

• Opioid Use Disorder (OUD) is a significant public health concern requiring effective treatment strategies.
• Extended-release naltrexone (XR-NTX) is an effective medication for OUD, but initiation can be challenging.
• Medically managed withdrawal often involves adjunctive medications to manage symptoms.

Purpose of the Study:

• To evaluate the impact of different thresholds for administering adjunctive medications (clonidine, clonazepam) during opioid withdrawal on initiating XR-NTX.
• To compare the probability of successful XR-NTX initiation under varying medication administration protocols.

Main Methods:

• Secondary analysis of a multisite clinical trial involving 415 adults with OUD.
• Utilized a longitudinal sequentially doubly robust estimator to assess XR-NTX initiation probability.
• Compared three regimes: no threshold, minimal withdrawal symptoms (COWS ≥ 3), and mild-to-moderate withdrawal symptoms (COWS ≥ 5) for medication administration.

Main Results:

• The probability of initiating XR-NTX by day 14 was highest (50.4%) under the no-threshold regime.
• Initiating XR-NTX was significantly higher (11.9 percentage points) when medications were given without a withdrawal symptom threshold compared to a mild-to-moderate threshold.
• No significant difference was observed between the no-threshold and minimal withdrawal symptom threshold regimes.

Conclusions:

• Daily administration of clonidine and clonazepam during the first five days of medically managed opioid withdrawal significantly enhances XR-NTX initiation.
• Healthcare providers may consider preemptive medication administration or managing even minimal withdrawal symptoms to improve XR-NTX initiation rates.
• Adjusting adjunctive medication thresholds can optimize treatment pathways for individuals with OUD seeking XR-NTX therapy.